New Delhi: Drug firm Cipla said it has received approval from the US health regulator for Lenalidomide capsule, a drug used to treat various types of cancer.

The company has received the final approval from the US Food and Drug Administration (USFDA) for the product in strengths of 5 mg, 10 mg, 15 mg, and 25 mg, Cipla said in a regulatory filing.

Cipla's Lenalidomide capsules are therapeutic equivalent generic versions of Bristol Myers Squibb's Revlimid (Lenalidomide) capsules.

Click for more on USFDA

Lenalidomide is an immunomodulatory prescription drug indicated for several hematological malignancies in adults, such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Depending on the type of cancer, it can be used as monotherapy or in combination as a part of the first-line regimen, maintenance regimen, or relapsed setting.

According to IQVIA (IMS Health), Revlimid capsules had sales of around USD 2.58 billion in the US for the 12-month period ending June 2022.

The product will be available for shipping soon, Cipla noted.

Shares of the company were trading 1.95 percent up at Rs 1,061 apiece on the BSE.

Other drugs approval by USFDA

USFDA approves Venlafaxine, Pregabalin extended release tablets

USFDA gives nod for SPEVIGO To treat Generalized Pustular Psoriasis Flares

USFDA gives approval to Loperamide HCL and Simethicone Tablets

USFDA gives final approval for Chlorthalidone Tablets USP

USFDA gives tentative nod for Dasatinib tablets

USFDA gives approval for this Contraceptive

CDSCO approves intra Nasal Vaccine for C-19 in adults

USFDA approves Venlafaxine, Pregabalin extended release tablets

IPC alerts about Cefoperazone induced coagulopathy

USFDA gives nod for SPEVIGO To treat Generalized Pustular Psoriasis Flares

Safe blood transfusion is still a challenge for thalassemia patients

Drug recall: Zydus, Lupin recall products due to this issue

Pharmacy Council: Elections process to elect 6 members begins

Bulk drug park: Booster shot for Pharma companies

NPPA seeks pricing details of Sodium Chloride 0.45% injection

Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/?p=40970